GrowBLOX Sciences Aktie [WKN DE: A11218 / ISIN: US3998471029]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu GrowBLOX Sciences Inc

22.05.18		GB Sciences Will Now Serve A Greatly Expanded Patient Base In Louisiana With The Addition Of Autism, Glaucoma, Parkinson's, PTSD, Intractable Pain And Severe Muscle Spasms To The List Of Ailments... (PR Newswire)
22.05.18		GB Sciences Will Now Serve A Greatly Expanded Patient Base In Louisiana With The Addition Of Autism, Glaucoma, Parkinson's, PTSD, Intractable Pain And Severe Muscle Spasms To The List Of Ailments... (PR Newswire)
09.05.18		GB Sciences' Acquisition Of NevadaPURE Is Terminated (PR Newswire)
09.05.18		GB Sciences' Acquisition Of NevadaPURE Is Terminated (PR Newswire)
17.04.18		Exploratory IND Is Planned Using GB Sciences' Proprietary Mixtures of Botanical Compounds to Provide the Highest Efficacy for Patients (PR Newswire)
17.04.18		Exploratory IND Is Planned Using GB Sciences' Proprietary Mixtures of Botanical Compounds to Provide the Highest Efficacy for Patients (PR Newswire)
12.04.18		GB Sciences Announces the Appointment of John B. Davis as Executive VP and General Counsel (PR Newswire)
12.04.18		GB Sciences Announces the Appointment of John B. Davis as Executive VP and General Counsel (PR Newswire)
10.04.18		GB Sciences Pursues FDA-Registered, First-in-Human Trial of Cannabis-based Therapy for Parkinson's Disease (PR Newswire)
10.04.18		GB Sciences Pursues FDA-Registered, First-in-Human Trial of Cannabis-based Therapy for Parkinson's Disease (PR Newswire)
04.04.18		GB Sciences Completes Nanotechnology Transfer of Exclusively-Licensed, Cannabinoid-Based, Time-Released Neuropathic Pain Formula (PR Newswire)
04.04.18		GB Sciences Completes Nanotechnology Transfer of Exclusively-Licensed, Cannabinoid-Based, Time-Released Neuropathic Pain Formula (PR Newswire)
28.03.18		GB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues (PR Newswire)
28.03.18		GB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues (PR Newswire)
15.03.18		GB Sciences Sponsors "Innovation in Medical Cannabis Therapies" Symposium (PR Newswire)
15.03.18		GB Sciences Sponsors "Innovation in Medical Cannabis Therapies" Symposium (PR Newswire)
27.02.18		GB Sciences, Inc. Enters A New Market by Signing a Contract Farming Agreement for the Development of Boutique Hemp Genetics with the Colorado Hemp Project (PR Newswire)
27.02.18		GB Sciences, Inc. Enters A New Market by Signing a Contract Farming Agreement for the Development of Boutique Hemp Genetics with the Colorado Hemp Project (PR Newswire)
21.02.18		GB Sciences Receives Issuance of Its Cannabis Oil Production License (PR Newswire)
21.02.18		GB Sciences Receives Issuance of Its Cannabis Oil Production License (PR Newswire)
14.02.18		GB Sciences Partners with Wellcana Group, LLC. in the Development of Medical Cannabis in Louisiana (PR Newswire)
14.02.18		GB Sciences Partners with Wellcana Group, LLC. in the Development of Medical Cannabis in Louisiana (PR Newswire)
05.02.18		GB Sciences Files a Nonprovisional Patent Application for Cannabis-Based Anti-Inflammatory Therapies Including Arthritis, Asthma, Eczema and More (PR Newswire)
05.02.18		GB Sciences Files a Nonprovisional Patent Application for Cannabis-Based Anti-Inflammatory Therapies Including Arthritis, Asthma, Eczema and More (PR Newswire)
25.01.18		GB Sciences Welcomes Dr. Zoltan Mari, A Nationally Recognized Expert on the Study and Treatment of Parkinson's Disease to Their Scientific Advisory Board (PR Newswire)
25.01.18		GB Sciences Welcomes Dr. Zoltan Mari, A Nationally Recognized Expert on the Study and Treatment of Parkinson's Disease to Their Scientific Advisory Board (PR Newswire)
08.01.18		GB Sciences Is Maximizing the Production of Critical Medical Components from Specific Cannabis Strains (PR Newswire)
08.01.18		GB Sciences Is Maximizing the Production of Critical Medical Components from Specific Cannabis Strains (PR Newswire)
26.12.17		GB Sciences' Chief Science Officer, Dr. Andrea Small-Howard, Has Been Invited to Join the Medical Cannabis in Neuroscience Panel at The Neuroscience Innovation Forum for BD&L and Investment in... (PR Newswire)
26.12.17		GB Sciences' Chief Science Officer, Dr. Andrea Small-Howard, Has Been Invited to Join the Medical Cannabis in Neuroscience Panel at The Neuroscience Innovation Forum for BD&L and Investment in... (PR Newswire)
13.12.17		GB Sciences: Develops Extremely High THC Content Cannabis Strain With Maximized Terpene Levels To Increase Medical Benefits (PR Newswire)
13.12.17		GB Sciences: Develops Extremely High THC Content Cannabis Strain With Maximized Terpene Levels To Increase Medical Benefits (PR Newswire)
05.12.17		GB Sciences Announces Tissue Propagation Breakthrough In Commercial Cannabis Cultivation (PR Newswire)
05.12.17		GB Sciences Announces Tissue Propagation Breakthrough In Commercial Cannabis Cultivation (PR Newswire)
15.11.17		GB Sciences Exceeds Its Gross Revenue Projections for October, Doubles the Industry Average Yield Per Active Flower Light (PR Newswire)
15.11.17		GB Sciences Exceeds Its Gross Revenue Projections for October, Doubles the Industry Average Yield Per Active Flower Light (PR Newswire)
13.11.17		GB Sciences is Happy (PR Newswire)
01.11.17		GB Sciences Inducts Scientific Advisory Board: Dr. Andrea Small-Howard of GB Sciences, Dr. Helen Turner of Chaminade University, Dr. Norbert Kaminsky of Michigan State University, and Dr. (PR Newswire)
30.10.17		GB Sciences, Inc. Partners With Cura Cannabis Solutions And Enters The Lucrative Cannabis Oil Market In Nevada (PR Newswire)
26.10.17		GB Sciences Receives The Prestigious 'Spirit Of The Law' Award (PR Newswire)
23.10.17		GB Sciences Increased Sales 400% Since First Harvest (PR Newswire)
17.10.17		GB Sciences Obtains Exclusive Worldwide License on a Time-Released Cannabinoid Formulation for Neuropathic Pain (PR Newswire)
10.10.17		Nanotechnology Research Collaboration with Universidad de Sevilla to Create Time-Released Formulation for GB Sciences' THC-Free Chronic Pain Therapy (PR Newswire)
18.09.17		Groundbreaking Collaboration Between A Major University And A Medical Cannabis Company (PR Newswire)
18.09.17		Innovative Partnership Forged Between LSU AgCenter And GB Sciences To Advance The Understanding Of The Cannabis Plant (PR Newswire)
14.09.17		Cannabis Legalization Gains Popularity (PR Newswire)
02.08.17		GB Sciences Joins With Los Coyotes Band Of Cahuilla And Cupeno Indians As It Enters The Gigantic California Cannabis Market (PR Newswire)
17.07.17		GB Sciences Initiates Cannabis-based Therapy Clinical Trials Consulting Services Agreement with Worldwide Clinical Trials, Inc. (PR Newswire)
10.07.17		GB Sciences Inc. Adds Provisional Nevada Recreational Cannabis License for Branded Recreational Products (PR Newswire)
05.07.17		GB Sciences Sells First Cannabis Harvest and Officially Enters Revenue Mode (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Pierer-Aktie letztlich zweistellig höher: KTM ist insolvent - Antrag auf Sanierung in Eigenverwaltung

Solana Kurs Prognose: 300 US-Dollar noch in diesem Jahr?

Pierer Mobility-Aktie unter Druck: KTM-Pleite - Schockstarre in der Region und bei den Zulieferern - Land OÖ signalisiert Bereitschaft Beschäftigten zu helfen

voestalpine-Aktie zieht an: Erste Group stuft Aktie von "Accumulate" auf "Buy" hoch

Rosenbauer erwartet kein Problem bei Kapitalerhöhung wegen KTM-Pleite - Rosenbauer-Aktie fester

Pierer Mobility-Aktie bricht ein: KTM steht vor Insolvenz

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	30.11.2024 20:30
Kaufwert:	EUR
	Hinzufügen Speichern